Wockhardt in Vaccine Manufacturing Partnership With Serum Life Sciences

March 31, 2022

Cleary Gottlieb is representing Wockhardt, the global pharmaceutical and biotechnology major, in its agreement with Serum Life Sciences Ltd (Serum), a subsidiary of the Serum Institute of India, one of the world’s largest vaccine manufacturers, to collaborate on the delivery of a global vaccine program.

Under the terms of the agreement signed with Serum, Wockhardt will fill and finish up to 150 million doses annually of multiple vaccines pursuant to a profit sharing arrangement between the parties. The required manufacturing capacity will be created through the construction of a new sterile fill and finish facility at Wockhardt’s site in Wrexham, North Wales.

Wockhardt is listed on the Bombay Stock Exchange and the National Stock Exchange of India. In the United Kingdom, Wockhardt has been a longstanding supplier to the NHS and employs over 400 people at its high-tech manufacturing facility in Wrexham.

For more information, please see the official press release here.